When a rogue cell starts proliferating out of control, the first responders on the scene should be the body’s own immune cells—for example, natural killer (NK) cells, which use toxic molecules to ...

These findings suggest that KIR2DS2-positive (KIR2DS2+) natural killer (NK) cells could be an attractive therapeutic target for in vivo strategies, although enhanced effector function is lost during ...

Acute Myeloid Leukemia (AML) remains one of the most challenging hematological malignancies to treat, with relapse and refractory cases continuing to pose significant hurdles. Traditional therapies ...

Immune evasion continues to limit the effectiveness of cancer immunotherapies. Among emerging regulatory molecules, transfer RNA-derived small RNAs (tsRNAs of 13-48 nucleotides), generated through ...